SCHEMBL1763070

SCHEMBL1763070

Cc1cc(C)c(S(=O)(=O)c2c[nH]nn2)c(C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 6/20 0.44
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
MMP13 P45452 1/20 0.38
F2 P00734 2/20 0.35
PRSS1 P07477 2/20 0.35
PRSS2 P07478 2/20 0.35
PRSS3 P35030 2/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 2/20 0.33
MAPK1 P28482 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
NR2F2 P24468 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1976807 0.74 GAA (0.52) RAPGEF4CA1CA2MEN1KMT2A
SCHEMBL10601772 0.72 RAPGEF4 (0.44) RAPGEF4CA1CA2MMP1MMP2
SCHEMBL8782170 0.72 RAPGEF4 (0.49) RAPGEF4CA1CA2MMP1MMP2
SCHEMBL2047218 0.72 RAPGEF4 (0.67) RAPGEF4CA1CA2MMP1MMP2
SCHEMBL10587121 0.70 ALDH1A1 (0.38) MEN1KMT2AALDH1A1LMNANR2F2
SCHEMBL5531150 0.69 RAPGEF4 (0.44) RAPGEF4CA1CA2MMP1MMP2
SCHEMBL21621365 0.68 SMN1; SMN2 (0.35) CA1CA2ALDH1A1LMNAHTT
SCHEMBL9705788 0.67 ALDH1A1 (0.39) RAPGEF4CA1CA2MMP1MMP2
SCHEMBL6820319 0.66 HTR6 (0.48) ALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL4735410 0.66 RAPGEF4 (0.44) RAPGEF4CA1CA2MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8614312-B2 Method for preparing nucleotides and related analogues by synthesis on soluble substrate, and biological tools thus prepared CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-24 US claimed
US-20110118454-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-05-19 US claimed
JP-57088196-A None JP disclosed
JP-57206696-A None JP disclosed
JP-57206697-A None JP disclosed
US-8614312-B2 Method for preparing nucleotides and related analogues by synthesis on soluble substrate, and biological tools thus prepared CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-24 US disclosed
US-20110118454-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-05-19 US disclosed
EP-2265624-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED Centre National de la Recherche Scientifique (FR) 2010-12-29 EP disclosed
WO-2009115694-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2009-09-24 WO disclosed
US-5807837-A ADMINISTERING TO TREAT HIV INFECTIONS TO INHIBIT THE REPLICATION OF FOREIGN NUCLEIC ACIDS IN A NORMAL CELL SANKYO COMPANY, LIMITED (JP) 1998-09-15 US disclosed
US-5674856-A TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS, INCLUDING AIDS AND TUMORS SANKYO COMPANY, LIMITED (JP) 1997-10-07 US disclosed
US-5032680-A Antitumor KURARAY CO., LTD. (JP) 1991-07-16 US disclosed
US-5008191-A Pesticides, insecticides, anthelmintics, antibiotics SANKYO COMPANY LIMITED (JP) 1991-04-16 US disclosed
EP-0274871-A1 Macrolide compounds, their preparation and their use Sankyo Company Limited (JP) 1988-07-20 EP disclosed
US-4605645-A ANTITUMOR AGENTS TEIJIN LIMITED (JP) 1986-08-12 US disclosed
EP-0081386-B1 5-FLUORO-2'-DEOXYURIDINE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF TEIJIN LIMITED (JP) 1985-05-29 EP disclosed
EP-0081386-A1 5-Fluoro-2'-deoxyuridine derivatives and a process for the preparation thereof TEIJIN LIMITED (JP) 1983-06-15 EP disclosed
JP-S57206696-A DODECANUCLEOTIDE AND ITS PREPARATION EISAI CO LTD 1982-12-18 JP disclosed
JP-S57206697-A NOVEL NUCLEOTIDE AND ITS PREPARATION EISAI CO LTD 1982-12-18 JP disclosed
JP-S5788196-A PRODUCTION OF OLIGONUCLEOTIDES EISAI CO LTD 1982-06-01 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118454-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED PNP, NUDT1, DUT RAPGEF4 939/4885CA1 3158/4885CA2 4552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.